Autres langues Abbott Laboratories

Actions

ABT

US0028241000

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX 17:40:33 02/10/2026			Varia. 5j.	Varia. 1 janv.
96,90 ^USD	+0,21 %		-4,55 %	-22,84 %

13:47	Le test sanguin de Grail pour le dépistage du cancer proche d’une autorisation historique de la FDA, mais la prise en charge par les assurances reste incertaine	RE
13:00	Abbott Laboratories : Rothschild & Co Redburn réajuste son opinion à la hausse	ZM

Autres langues

15:29	Schwacher Arbeitsmarkt gibt Aktien Auftrieb
15:21	Afternoon Meeting: La debilidad del empleo impulsa a las bolsas
15:07	Weak Jobs Lead to Stronger Stocks
13:47	Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
12:03	Analystenempfehlungen: Adidas, Hensoldt, Lindt, Airbnb, Hewlett Packard, Nike…
10:50	Analyst recommendations: Airbnb, Hewlett Packard Enterprise, Fair Isaac, Nike…
30/09	Abbott Launches Simplescreen Crc Blood Test in the U.S
30/09	Abbott Launches SimpleScreen Blood Test for Colorectal Cancer
30/09	Abbott hosts conference call for third-quarter earnings
30/09	Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
25/09	Abbott Laboratories : Landmark study in people with Type 2 diabetes using basal insulin shows continuous glucose monitoring, including Abbott’s Libre technology, associated with lower risk of death and cardiovascular complications
24/09	US FDA advisers endorse Grail cancer test's benefits in key vote
23/09	Abbott and Berry Street team up on personalized nutrition tracking
23/09	US companies face rise in cyber attacks
23/09	Abbott and Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
23/09	Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
21/09	Grail rallies as FDA staff flags no major concerns for multi-cancer test
18/09	Trinity Heart Experts First in the Quad Cities to Use New Afib Technology
17/09	Abbott Laboratories Declares Quarterly Dividend, Payable on Nov. 16, 2026
17/09	Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Nov. 16 to Holders of Record on Oct. 15
17/09	Abbott declares 411th consecutive quarterly dividend
15/09	Abbott Announces First Canadian Use of Volt Pulsed Field Ablation System to Treat Atrial Fibrillation
15/09	First Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care
15/09	Abbott to pay $385M over infant formula contamination probe
14/09	Abbott agrees to settlement over closure of largest baby formula plant in the US